Momenta Phamaceuticals (MNTA) Posts Surprise Q4 Loss; Guides OpEx
MNTA Hot Sheet
EPS Growth %: -108.8%Financial Fact:
Basic (in shares): 50.24M
Today's EPS Names:
TARO, BRLI, TLB, More
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 EPS of ($0.02), $0.29 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $29.5 million versus the consensus estimate of $38.59 million.
Sees total operating expenses, excluding stock compensation and royalties payable to MIT, and net of collaborative revenues, increasing to approximately $22 to $28 million per quarter for 2012.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Sees total operating expenses, excluding stock compensation and royalties payable to MIT, and net of collaborative revenues, increasing to approximately $22 to $28 million per quarter for 2012.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Patterson Companies, Inc. (PDCO) Tops Q4 EPS by 5c; Guides FY12
- Pandora (P) Blows Up Expectations as Listener Hours Rip; Guides FY13 Ahead of Views
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
